138 related articles for article (PubMed ID: 38241758)
1. In the era of antiviral trials for MS, the answer lies in the details.
Drosu N; Bjornevik K; Bilodeau PA; Yeh A; Lechner-Scott J; Hawkes CH; Giovannoni G; Levy M
Mult Scler Relat Disord; 2024 Feb; 82():105444. PubMed ID: 38241758
[No Abstract] [Full Text] [Related]
2. EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapies.
Drosu N; Giovannoni G; Lechner-Scott J; Hawkes C; Yeh A; Levy M
Mult Scler Relat Disord; 2022 Aug; 64():104007. PubMed ID: 35803161
[No Abstract] [Full Text] [Related]
3. Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.
Lie IA; Rød BE; Kvistad SS; Holmøy T; Myhr KM; Torkildsen Ø; Wergeland S
Mult Scler Relat Disord; 2023 Feb; 70():104530. PubMed ID: 36701908
[TBL] [Abstract][Full Text] [Related]
4. Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective.
Drosu N; Giovannoni G; Pohl D; Hawkes C; Lechner-Scott J; Levy M
Mult Scler Relat Disord; 2021 Jul; 52():103087. PubMed ID: 34139660
[No Abstract] [Full Text] [Related]
5. Epstein-Barr virus and multiple sclerosis.
Lovett-Racke AE; Racke MK
Arch Neurol; 2006 Jun; 63(6):810-1. PubMed ID: 16769860
[No Abstract] [Full Text] [Related]
6. Antiviral therapy with tenofovir in MS.
Torkildsen Ø; Myhr KM; Brugger-Synnes P; Bjørnevik K
Mult Scler Relat Disord; 2024 Mar; 83():105436. PubMed ID: 38217968
[TBL] [Abstract][Full Text] [Related]
7. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
9. Is multiple sclerosis a glymphaticopathy?
Alghanimy AA; Giovannoni G; Lechner-Scott J; Levy M; Yeh EA; Hawkes CH
Mult Scler Relat Disord; 2023 Dec; 80():105141. PubMed ID: 38039696
[No Abstract] [Full Text] [Related]
10. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: no.
Salzer J; Myhr KM
Mult Scler; 2013 Nov; 19(13):1692-3. PubMed ID: 24218487
[No Abstract] [Full Text] [Related]
11. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
12. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
13. Antiviral immune response in patients with multiple sclerosis, healthy siblings and twins.
Ristori G; Mechelli R; Anderson J; Mengoni F; Sauzullo I; Annibali V; Cannoni S; Aloisi F; James JA; Salvetti M
Mult Scler; 2010 Dec; 16(12):1527-8. PubMed ID: 20798134
[No Abstract] [Full Text] [Related]
14. Epstein-Barr virus candidate genes and multiple sclerosis.
Claire Simon K; Schmidt H; Loud S; Ascherio A
Mult Scler Relat Disord; 2015 Jan; 4(1):60-4. PubMed ID: 25787055
[TBL] [Abstract][Full Text] [Related]
15. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model.
Jog NR; McClain MT; Heinlen LD; Gross T; Towner R; Guthridge JM; Axtell RC; Pardo G; Harley JB; James JA
J Autoimmun; 2020 Jan; 106():102332. PubMed ID: 31515129
[TBL] [Abstract][Full Text] [Related]
16. Impact of genetic variation on the molecular mimicry between Anoctamin-2 and Epstein-Barr virus nuclear antigen 1 in Multiple Sclerosis.
Sepúlveda N
Immunol Lett; 2021 Oct; 238():29-31. PubMed ID: 34310987
[No Abstract] [Full Text] [Related]
17. Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
Wang Z; Kennedy PG; Dupree C; Wang M; Lee C; Pointon T; Langford TD; Graner MW; Yu X
J Neuroimmune Pharmacol; 2021 Sep; 16(3):567-580. PubMed ID: 32808238
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of IL-1β and IL-6 Expression following EBNA-1 and BRLF-1 Peptide Treatment in Epstein-Barr Virus-Positive Multiple Sclerosis Patients.
Kianfar R; Ravanshad M; Ghiass MA; Rafiee N; Shayeghpour A; Maleki A
Intervirology; 2022; 65(3):144-150. PubMed ID: 35158367
[TBL] [Abstract][Full Text] [Related]
19. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis.
De Jager PL; Simon KC; Munger KL; Rioux JD; Hafler DA; Ascherio A
Neurology; 2008 Mar; 70(13 Pt 2):1113-8. PubMed ID: 18272866
[TBL] [Abstract][Full Text] [Related]
20. Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study.
Schlemm L; Giess RM; Rasche L; Pfuhl C; Wakonig K; Behrens JR; Scheibenbogen C; Bellmann-Strobl J; Paul F; Reimer U; Ruprecht K
J Neuroimmunol; 2016 Aug; 297():56-62. PubMed ID: 27397076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
